Boehringer Ingelheim has expanded access to a digital adherence programme that helps COPD patients take their medicines as prescribed by offering them educational and motivational tools.
AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
